Drug Profile

AMB 101 - Evopoint Biosciences

Alternative Names: AMB 101-Evopoint Biosciences

Latest Information Update: 23 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evopoint Biosciences
Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

16 Jan 2023 AmMax Bio plans to submit IND application in mid-2023
13 Jan 2023 AmMax Bio and Evopoint Biosciences plans a first in human trial in the second half of 2023
09 Jan 2023 AmMax Bio enters into an exclusive option agreement with Evopoint Biosciences for AMB 101 in Solid tumors, in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com